Research prototype, not medical advice.

In an open pilot trial (14 patients with pulmonary fibrosis), D+Q improved physical function and was feasible.

Confidence
Debated
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Chronic inflammationDasatinib + quercetin (D+Q)Idiopathic pulmonary fibrosisSenescence-associated secretory phenotype (SASP)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice et al. · EBioMedicine 2019
— Verified